Business & Industry

The Food and Drug Administration is looking to speed the development when it comes to biosimilars and has announced new guidelines, which would no longer want the makers of copycat biologics to indulge in human trials, therefore showing that...

In just a space of 24 hours, GSK, in its second pipeline-expanding deal, has gone on to license the rights to a drug for chronic obstructive pulmonary disease – COPD from Empirico, the US biotech, for $85 million, and...

KLN Logistics Group Limited announced a strategic partnership between its healthcare subsidiary, KLN Medical Limited (‘KLN Medical’), and global medical technology leader Siemens Healthineers AG (Stock Code SHL.DE). KLN Medical will serve as the exclusive distributor for Siemens Healthineers’...

With a focus on Adeno-Associated Virus (AAV), the worldwide market for Contract Development and Manufacturing Organizations (CDMMOs) that biomanufacture cell and gene therapies has shown spectacular development, estimated to reach $0.2313 billion in 2022. Based on projections, this market...

It is projected that the market for pharmaceutical contract manufacturing organizations (CMOs) would expand at a compound annual growth rate (CAGR) of 7.29 percent until the year 2028. This rise may be ascribed to the expanded pharmaceutical industry, which...

During the period of time from 2023 to 2029, the global market for cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is projected to grow at a compound annual growth rate (CAGR) of 17.5%. In 2022,...

Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...